MoonLake Immunotherapeutics MLTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $54.52M-2.7% | $56.01M-7.6% | $60.64M+21.9% | $49.76M+36.5% | $36.46M-9.7% | ||
| $70.02M+7.4% | $65.22M-8.7% | $71.43M+17.7% | $60.7M+27.8% | $47.49M-4.2% | ||
| $70.02M+7.4% | $65.22M-8.7% | $71.43M+17.7% | $60.7M+27.8% | $47.49M-4.2% | ||
| $622K+151% | $248K+116% | $115K+21.1% | $95K-37.9% | $153K+273% | ||
| -$69.71M-11.7% | -$62.43M+10.5% | -$69.73M-26.3% | -$55.22M-38.2% | -$39.94M+12.4% | ||
| -$0.98-6.5% | -$0.92+16.4% | -$1.10-26.4% | -$0.87-38.1% | -$0.63+12.5% | ||
| 71.3M+10.6% | 64.5M+1.7% | 63.4M+0.1% | 63.3M+0.1% | 63.2M+0.6% | ||
| 71.3M+10.6% | 64.5M+1.7% | 63.4M+0.1% | 63.3M+0.1% | 63.2M+0.6% | ||
| -$69.99M-12.7% | -$62.11M+11.2% | -$69.97M-22.6% | -$57.09M-34.1% | -$42.56M+2.0% | ||
| $7.12M— | —— | $12.86M+809% | -$1.81M-16.5% | -$1.56M-137% | ||
| $10.1M+362% | -$3.86M-1,308% | -$274K-107% | $3.84M+1,508% | -$273K-105% | ||
| $30.64M-57.7% | $72.4M+14,982% | $480K— | $0-100% | $73.12M+48,325% | ||
| $98K— | —— | $88.4M+0.2% | $88.25M+56.9% | $56.25M+138% | ||
| -$66.29M-12.7% | -$58.79M-32.0% | -$44.54M+18.3% | -$54.53M-43.0% | -$38.14M+21.3% | ||
| -$359K-168% | $525K+6,463% | $8K-38.5% | $13K-86.3% | $95K— | ||
| $77K+138% | -$203K+20.4% | -$255K+86.6% | -$1.91M+30.8% | -$2.76M-227% | ||
| -$282K— | $0+100% | -$247K+87.0% | -$1.9M+28.8% | -$2.66M-221% | ||
| $3.21M-27.8% | $4.44M+9.6% | $4.05M-40.2% | $6.78M-4.5% | $7.1M+120% | ||
| -$69.18M-7.3% | -$64.47M+8.8% | -$70.69M-17.9% | -$59.96M-27.3% | -$47.11M+4.3% | ||
| -$70.02M-7.4% | -$65.22M+8.7% | -$71.43M-17.7% | -$60.7M-27.8% | -$47.49M+4.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is MoonLake Immunotherapeutics profitable?
- MoonLake Immunotherapeutics is not currently profitable: it reported a net loss of $257.1M over the trailing twelve months.
- What is MoonLake Immunotherapeutics's earnings per share?
- MoonLake Immunotherapeutics's diluted EPS over the trailing twelve months is $-3.87.
- Where does MoonLake Immunotherapeutics's income statement data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.